Recently added articles from HIV Treatment: ALERTS!:
The 14th Conference on Retroviruses and Opportunistic Infections (CROI): Los Angeles, February 25th-28th.(HIGHLIGHTS)
Jun 01, 2007 ... The 14th Conference on Retroviruses and Opportunistic Infections (CROI), held in Los Angeles from February 25th to the 28th, is one of the biggest HIV science conferences held each year. As in past years, the world's leading researchers presented their findings from work they have been ...
New drug profile: Maraviroc: it's different, it's strong, and it's almost here.(Drug overview)
Jun 01, 2007 ... What is it? Maraviroc (or Celsentri) is an HIV medication, the first of its kind. Maraviroc doesn't block HIV directly; instead, maraviroc binds to a human protein known as CCR5. This is one of the proteins HIV uses to enter human T cells. By binding to CCR5, maraviroc keeps HIV ...
HIV super strain revisited.(IN THE NEWS)
Jun 01, 2007 ... In the April 2005 edition of The Center for AIDS Information & Advocacy HIV Treatment ALERTS! we reported the strange case of a 40-something year old, gay man in New York City (referred to as NYC) who appeared to be newly infected with a form or "strain" of HIV that was resistant to the 3 ...
Green tea: fact or fiction.(treatment news)
Jun 01, 2007; Nance, Christina L. ... Scientists have discovered that a substance in green tea prevents HIV from attaching to our immune system cells by getting there first. According to researchers from Baylor College of Medicine in Houston and the University of Sheffield in the England, in a report that appears in the ...
Fuzeon update.(Brief article)
Jun 01, 2007 ... In January, new precautions were added to the labeling for the injectable HIV fusion inhibitor Fuzeon. The new information focuses on side effects reported when the Biojector 2000 needle-free device is used to inject Fuzeon. In addition, the correct injection sites are spelled out. ...
Sustiva drug interactions.(FDA BITS)
Jun 01, 2007 ... In January, new precautions were added to the labeling for the "non-nuke" Sustiva concerning potential drug interactions. Patients taking Sustiva should not take Hismanal (astemizole), Vascor (bepridil), Propulsid (cisapride), Versed (midazolam), Orap (pimozide), Halcion (triazolam), or ...
Anemia treatment warnings.(treatment news)
Jun 01, 2007 ... In March, the Food and Drug Administration (FDA) issued a warning about the use of Aranesp, Epogen, and Procrit in all patients. These drugs are called erythropoiesis-stimulating agents (ESAs). They stimulate a patient's bone marrow to produce more red blood cells and are given to patients ...
Radiesse approved.(treatment news)
Jun 01, 2007 ... Last December, the Food and Drug Administration (FDA) approved Radiesse, an injectable filler to correct signs of facial lipoatrophy (loss of fat) in HIV+ people. Until now, Sculptra was the only facial filler approved by the FDA for this condition. Radiesse contains a synthetic (or ...
Definitions.
Jun 01, 2007 ... Anemia: low levels of red blood cells or hemoglobin in the blood, resulting in feelings of tiredness or fatigue. Antibody: proteins produced by the immune system to fight specific bacteria, viruses, or other antigens. Chemokine antagonist: (also known as CCR5, short ...
